Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SURG
SURG logo

SURG Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Surgepays Inc (SURG) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.420
1 Day change
-4.55%
52 Week Range
3.450
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

SurgePays Inc (SURG) is not a strong buy at this moment for a beginner investor with a long-term strategy. The technical indicators are bearish, options sentiment is neutral, and there are no significant positive catalysts or financial performance data to justify immediate investment. The stock may be worth monitoring for future opportunities, but it does not align with the user's investment goals right now.

Technical Analysis

The technical indicators for SURG are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 33.471, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its S1 support level of 0.407, with resistance levels at 0.48 and 0.552.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
4

Positive Catalysts

  • NULL identified. There is no recent news or significant trading activity by insiders, hedge funds, or influential figures.

Neutral/Negative Catalysts

  • Price target was recently lowered by Ascendiant from $9.75 to $5 due to weaker Q4 revenue. Technical indicators are bearish, and the stock shows a low probability of significant short-term gains.

Financial Performance

No financial data available for analysis. The company reported weaker Q4 revenue, but a growth rebound is expected in 2026 according to analysts.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Ascendiant maintains a Buy rating but has lowered the price target from $9.75 to $5 due to weaker Q4 revenue. Analysts expect a growth rebound in 2026.

Wall Street analysts forecast SURG stock price to rise
2 Analyst Rating
Wall Street analysts forecast SURG stock price to rise
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.440
sliders
Low
9.75
Averages
9.75
High
9.75
Current: 0.440
sliders
Low
9.75
Averages
9.75
High
9.75
Ascendiant
Buy
to
Buy
downgrade
$5
AI Analysis
2026-04-17
Reason
Ascendiant
Price Target
$5
AI Analysis
2026-04-17
downgrade
Buy
to
Buy
Reason
Ascendiant lowered the firm's price target on SurgePays to $5 from $9.75 and keeps a Buy rating on the shares. The company reported weaker Q4 revenue but should see a growth rebound in 2026, the analyst tells investors in a research note.

People Also Watch